- Home
- FLO vs MLYS Comparison
FLO vs MLYS Comparison
Compare FLO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLO
- MLYS
- Stock Information
- Founded
- FLO 1919
- MLYS 2019
- Country
- FLO United States
- MLYS United States
- Employees
- FLO N/A
- MLYS N/A
- Industry
- FLO Packaged Foods
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- FLO Consumer Staples
- MLYS Health Care
- Exchange
- FLO Nasdaq
- MLYS Nasdaq
- Market Cap
- FLO 3.2B
- MLYS 3.1B
- IPO Year
- FLO N/A
- MLYS 2023
- Fundamental
- Price
- FLO $12.58
- MLYS $38.97
- Analyst Decision
- FLO Hold
- MLYS Strong Buy
- Analyst Count
- FLO 4
- MLYS 6
- Target Price
- FLO $16.50
- MLYS $42.60
- AVG Volume (30 Days)
- FLO 4.7M
- MLYS 1.5M
- Earning Date
- FLO 11-07-2025
- MLYS 11-10-2025
- Dividend Yield
- FLO 7.86%
- MLYS N/A
- EPS Growth
- FLO 71.08
- MLYS N/A
- EPS
- FLO 1.04
- MLYS N/A
- Revenue
- FLO $5,098,751,000.00
- MLYS N/A
- Revenue This Year
- FLO $4.24
- MLYS N/A
- Revenue Next Year
- FLO $0.08
- MLYS N/A
- P/E Ratio
- FLO $12.12
- MLYS N/A
- Revenue Growth
- FLO N/A
- MLYS N/A
- 52 Week Low
- FLO $12.42
- MLYS $8.24
- 52 Week High
- FLO $23.44
- MLYS $41.09
- Technical
- Relative Strength Index (RSI)
- FLO 28.98
- MLYS 67.39
- Support Level
- FLO $12.85
- MLYS $35.32
- Resistance Level
- FLO $13.28
- MLYS $40.91
- Average True Range (ATR)
- FLO 0.28
- MLYS 1.99
- MACD
- FLO 0.04
- MLYS -0.91
- Stochastic Oscillator
- FLO 19.77
- MLYS 64.76
About FLO Flowers Foods Inc.
Flowers Foods Inc is an American company producing bakery food for retail and foodservice across the United States. The product portfolio includes fresh breads, buns, rolls, snack cakes, and tortillas. The company distributes to supermarkets, convenience stores, and restaurants. The key brands are Nature's Own, Wonder, Tastykake, Canyon Bakehouse, DKB.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.